Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees. On...
Tag : biopharmaceutical company
Rondo Therapeutics Publishes Preclinical Data on RNDO-564 Therapy
RNDO-564 is designed to deliver safe and robust tumor killing activity in Nectin-4 positive tumors. RNDO-564 utilizes a novel mechanism of action for the treatment...
Savara Secures Up to $200M Non-Dilutive Debt Financing
Includes $30M at Close to Refinance Existing Debt Facility Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today...
Celltrion’s Remdantry™ to launch in Canada on April 1, 2025
Celltrion, Inc., a leading global biopharmaceutical company, announced that Remdantry™ will be available in Canada as of April 1, 2025. Remdantry™, previously known as Inflectra®,...
Newron Nominates Dr. Chris Martin as Independent Chairman
Expected to succeed Dr. Ulrich Köstlin who has notified Newron of his intention to retire after 12 years of service as Chairman of its Board...
RedHill Biopharma to Submit Talicia® for UK Approval
RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA’s2 new fast-track approval process, referencing FDA approval, with potential UK approval in Q4/25 Listed...
iOncologi Appoints Dr. Mona Flores and Mr. Paolo Fundarò to Board
iOncologi, Inc. (www.ioncologi.com), a clinical-stage biopharmaceutical company pioneering novel immunotherapies for cancer treatment, today announced the appointment of Dr. Mona Flores and Mr. Paolo Fundarò to its...
InnoCare Presents ICP-488 Data for Psoriasis at 2025 AAD
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the data of...
ENCell’s EN001 Gets FDA Orphan Drug Designation for CMT
ENCell, a leading biopharmaceutical company for cell and gene therapy CDMO and novel drug development, announced today that its investigational drug EN001 has been granted...
Nielsen BioSciences Completes Enrollment in Phase 3 CANDIN Trial
325 subjects enrolled across the United States and Japan in the first Phase III clinical trial for the treatment of warts in children and adults....
Emalex Biosciences’ Lead Candidate Hits Endpoints in TS Study
Topline data from Phase 3 study in patients with Tourette syndrome shows statistical significance between ecopipam and placebo for both the primary efficacy endpoint in...
MAIA Biotechnology Announces $1.43M Private Placement
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive...
Terns Pharmaceuticals Names Andrew Gengos CFO
Seasoned public company CFO with 25 years of leadership experience in biotech Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product...
Alzamend Neuro Completes Novel Head Coil for Phase II Trials
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy, Alzheimer’s disease,...